Lactobacillus rhamnosus, LGG®
- the world’s most documented probiotic strain
The real LGG® from Chr. Hansen is the world’s most documented probiotic strain.
Chr. Hansen’s Lactobacillus rhamnosus, LGG®
The LGG® strain was isolated from a human intestine sample in 1985.1
The LGG® strain has been used worldwide since 1990 as an ingredient in food and dietary supplements, with no known safety issues. The LGG® strain has been referenced in more than 250 publications describing human scientific studies.
The strain has been studied across various health areas, in newborns,2 preterm babies,3 children,4, 5, 6 pregnant women,7, 8 adults,9 and in the elderly,10 with no known safety issues.
The real LGG® by Chr. Hansen is the one used in more than 75% of all scientific study publications investigating Lactobacillus rhamnosus GG.
LGG® from Chr. Hansen has been associated with several health benefits
In children, some of the most researched health areas with the LGG® strain are:
Loose and watery stools
LGG® has been associated with fewer instances2 and shorter episodes of loose and watery stools6, 11, 12 and a faster improvement of the consistency of stools.4,12
Health conditions related to hospitalization
LGG® has been associated with fewer hospitalization-related digestive system conditions5 and fewer instances of respiratory tract discomfort that can occur following hospitalization.5
Immune challenges related to respiratory health
LGG® has been associated with fewer respiratory challenges,5, 13 fewer instances of respiratory challenges that last more than three days,5, 13 and significantly less days with signs of respiratory discomfort.13
Based on a scientific and microbiological evaluation, LGG® has been associated with more healthy teeth,14 and with lower levels of specific bacteria that contribute to poor oral health.15
In adults, some of the most researched health areas with the LGG® are:
LGG® has been associated with a reduction in the incidence of loose stools that travelers commonly experience when traveling in countries, regions and areas which present more chance of being exposed to unfamiliar bacteria.9
LGG® probiotic supplementation has been associated with significantly higher levels of antibodies (natural proteins integral to immune system function), which suggests support for immune health.16
SafetyLGG® is safe for human consumption and has been granted QPS (Qualified Presumption of Safety) status in Europe17 and has been the subject of a GRAS (Generally Recognized as Safe) notice to the US Food and Drug Administration,18 with no safety issues.
LGG® is a registered trademark of Chr. Hansen.
The article is provided for informational purposes regarding probiotics and is not meant to suggest that any substance referenced in the article is intended to diagnose, cure, mitigate, treat, or prevent any disease.
At Chr. Hansen, our strains are backed by science. All of our probiotic strains are supported by clinical documentation. Learn more about the beneficial effects our strains have on different health areas.
- Goldin BR, et al. Dig Dis Sci. 1992;37(1):121-8. (PubMed)
- Arvola T, et al.Pediatrics. 1999;104(5):e64. (PubMed)
- Underwood MA, et al. J Pediatr Gastroenterol Nutr. 2009;48(2):216-25. (PubMed)
- Vanderhoof JA, et al.The Journal of Pediatrics. 1999;135(5):564-8. (PubMed)
- Hojsak I, et al.Pediatrics. 2010;125(5):e1171-7. (PubMed)
- Isolauri E, et al. Pediatrics. 1991;88(1):90-7. (PubMed)
- Gueimonde M, et al.J Pediatr Gastroenterol Nutr. 2006;42(2):166-70. (PubMed)
- Lahtinen SJ, et al.J Allergy Clin Immunol. 2009;123(2):499-501. (PubMed)
- Hilton E, et al. J Travel Med. 1997;4(1):41-3. (PubMed)
- Hatakka K, et al.J Dent Res. 2007;86(2):125-30. (PubMed)
- Sindhu KNC, et al.Infectious Diseases Society of America. 2014;58(8):1107-15. (PubMed)
- Aggarwal S, et al.Indian J Med Res. 2014;139(3):379-85. (PubMed)
- Hojsak I, et al.Clin Nutr. 2010;29(3):312-6. (PubMed)
- Nase L, et al.Caries Res. 2001;35(6):412-20. (PubMed)
- Glavina D, et al.Coll Antropol. 2012;36(1):129-32. (PubMed)
- Davidson LE, et al. Eur J Clin Nutr. 2011;65(4):501-7. (PubMed)
- EFSA Panel on Biological Hazards (BIOHAZ). EFSA Journal. 2015;13:4331.
- Food and Drug Administration. GRAS Notice Inventory > Agency Response Letter. GRAS Notice No GRN 000049. 2002.